11-Sep-2026
Catalyst Watch: FOMC blockbuster, Salesforce event, and 24-hour trading talk
Seeking Alpha News (Fri, 11-Sep 3:00 PM ET)
Theravance facing several lawsuits seeking to block Zymeworks acquisition
Seeking Alpha News (Thu, 10-Sep 11:03 AM ET)
TipRanks (Thu, 10-Sep 9:30 AM ET)
Globe Newswire (Tue, 25-Aug 10:23 AM ET)
Zymeworks Announces Participation in Upcoming Investor Conferences
Globe Newswire (Tue, 11-Aug 6:00 AM ET)
Zymeworks Provides Corporate Update and Reports Second Quarter 2026 Financial Results
Globe Newswire (Thu, 6-Aug 4:05 PM ET)
Zymeworks to Report Second Quarter 2026 Financial Results on August 6, 2026
Globe Newswire (Thu, 16-Jul 6:00 AM ET)
PRNewswire (Mon, 6-Jul 11:20 AM ET)
Zymeworks to Acquire Theravance Biopharma, Inc.
Globe Newswire (Mon, 29-Jun 6:00 AM ET)
Gandeeva and Zymeworks Use Cryo-EM to Accelerate Antibody Drug Discovery
PRNewswire (Thu, 18-Jun 8:00 AM ET)
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
Zymeworks trades on the NASDAQ stock market under the symbol ZYME.
As of September 11, 2026, ZYME stock price declined to $26.24 with 504,254 million shares trading.
ZYME has a beta of 0.23, meaning it tends to be less sensitive to market movements. ZYME has a correlation of 0.00 to the broad based SPY ETF.
ZYME has a market cap of $1.88 billion. This is considered a Small Cap stock.
Last quarter Zymeworks reported $5 million in Revenue and -$.62 earnings per share. This fell short of revenue expectation by $-14 million and missed earnings estimates by -$.22.
In the last 3 years, ZYME traded as high as $31.34 and as low as $6.02.
The top ETF exchange traded funds that ZYME belongs to (by Net Assets): VTI, VTWO, DFAS, DFMC, CANC.
ZYME has outperformed the market in the last year with a return of +60.8%, while the SPY ETF gained +17.4%. In the last 3 month period, ZYME beat the market returning +14.3%, while SPY returned +3.9%. However, in the most recent 2 weeks ZYME has underperformed the stock market by returning -7.2%, while SPY returned -0.7%.
ZYME support price is $25.48 and resistance is $27.39 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ZYME shares will trade within this expected range on the day.